Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for phase IIa and phase III evaluation
Shampa Das(AstraZeneca (United Kingdom)), Susan Raber(Pfizer (United States)), Todd Riccobene(AbbVie (United States)), Timothy J. Carrothers(AbbVie (United States)), M. Macpherson(UCB Pharma (Belgium)), Andrew Cristinacce, Rujia Xie(Pfizer (United States)), James G. Wright(University of Toronto), Alison Luckey(Global Antibiotic Research & Development Partnership), Lynn McFadyen(Pfizer (United Kingdom))
Cited by 0
Related Papers
A prospective population‐based study of the predictors of undergoing total joint arthroplasty
|Arthritis & Rheumatism|2006|206
Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study
|Journal of Antimicrobial Chemotherapy|2019|123
A Population-Based Nested Case-Control Study of the Costs of Hip and Knee Replacement Surgery
|Medical Care|2009|120
Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial
|The Lancet Infectious Diseases|2024|98
Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation
|European Journal of Clinical Pharmacology|2024|28